Engineering T7 RNA Polymerases for Improved mRNA Therapeutics Manufacturing

Richard Obexer; Sarah Lovelock

doi:10.1016/j.checat.2023.100559

Engineering T7 RNA Polymerases for Improved mRNA Therapeutics Manufacturing

Richard Obexer, Sarah Lovelock

Chemical Biology and Biological Chemistry

Research output: Contribution to journal › Article › peer-review

Abstract

To establish mRNA therapeutics as viable and cost-effective treatments for a wide range of diseases, mRNA manufacturing challenges must be addressed. In a recent issue of Nature Biotechnology, Rabideau and coworkers engineered a T7 RNA polymerase to reduce formation of immunostimulatory by-products that must otherwise be removed using chromatographic purification.

Original language	English
Article number	100559
Journal	Chem Catalysis
Volume	3
Issue number	3
Early online date	16 Mar 2023
DOIs	https://doi.org/10.1016/j.checat.2023.100559
Publication status	Published - 16 Mar 2023

Access to Document

10.1016/j.checat.2023.100559

Cite this

@article{5b3aa1af9caf4208a8c97787acde31f2,

title = "Engineering T7 RNA Polymerases for Improved mRNA Therapeutics Manufacturing",

abstract = "To establish mRNA therapeutics as viable and cost-effective treatments for a wide range of diseases, mRNA manufacturing challenges must be addressed. In a recent issue of Nature Biotechnology, Rabideau and coworkers engineered a T7 RNA polymerase to reduce formation of immunostimulatory by-products that must otherwise be removed using chromatographic purification. ",

author = "Richard Obexer and Sarah Lovelock",

year = "2023",

month = mar,

day = "16",

doi = "10.1016/j.checat.2023.100559",

language = "English",

volume = "3",

journal = "Chem Catalysis",

issn = "2667-1107",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Engineering T7 RNA Polymerases for Improved mRNA Therapeutics Manufacturing

AU - Obexer, Richard

AU - Lovelock, Sarah

PY - 2023/3/16

Y1 - 2023/3/16

N2 - To establish mRNA therapeutics as viable and cost-effective treatments for a wide range of diseases, mRNA manufacturing challenges must be addressed. In a recent issue of Nature Biotechnology, Rabideau and coworkers engineered a T7 RNA polymerase to reduce formation of immunostimulatory by-products that must otherwise be removed using chromatographic purification.

AB - To establish mRNA therapeutics as viable and cost-effective treatments for a wide range of diseases, mRNA manufacturing challenges must be addressed. In a recent issue of Nature Biotechnology, Rabideau and coworkers engineered a T7 RNA polymerase to reduce formation of immunostimulatory by-products that must otherwise be removed using chromatographic purification.

U2 - 10.1016/j.checat.2023.100559

DO - 10.1016/j.checat.2023.100559

M3 - Article

SN - 2667-1107

VL - 3

JO - Chem Catalysis

JF - Chem Catalysis

IS - 3

M1 - 100559

ER -

Engineering T7 RNA Polymerases for Improved mRNA Therapeutics Manufacturing

Abstract

Access to Document

Fingerprint

Cite this